ELU Intent-to-Use Trademark Application

USPTO received trademark application TM97413732 for 'ELU' under Intent-to-Use basis, filed 2022-05-17. The application covers downloadable and non-downloadable software for asset optimization, industrial automation, machine diagnostics, and infrastructure management processes across industrial, healthcare, and manufacturing sectors.

VOIX Voice Technology Software Trademark Application

USPTO published Notice of trademark application TM97567185 for VOIX (intent-to-use basis), covering voice technology software and associated hardware including smartphones, tablets, IoT devices, smartwatches, and computer equipment. The application was filed August 26, 2022, by an unnamed applicant. No regulatory compliance obligations or deadlines arise from this trademark filing notice.

CWM Intent-to-Use Trademark for Cookbooks

USPTO received intent-to-use trademark application TM97765845 for 'CWM' covering printed cookbooks and downloadable electronic cookbooks. The application establishes a priority filing date of January 24, 2023. The 'intent to use' basis indicates the applicant plans to use the mark in commerce but has not yet done so.

ERBB-2 Bispecific Antibody Combination Therapy Patent

The European Patent Office published EP3600412A1 for Merus B.V., covering a combination therapy using ERBB-2 targeting agents with bispecific antibodies that bind epitopes on both ERBB-2 and ERBB-3 extracellular domains for treating ERBB-2 and ERBB-2/ERBB-3 positive tumors. The patent application names four inventors and designates all major European contracting states.

Anti-HERV-K Envelope Antibody Patent

The European Patent Office published patent EP3570878A1 for Geneuro SA and the U.S. Department of Health and Human Services covering anti-HERV-K envelope antibodies and their therapeutic applications. The patent is directed to antibodies targeting neurological conditions (A61P 25/28) and neuromuscular disorders (A61P 21/04, A61P 21/00). Designated states include all major European jurisdictions.

Immune Checkpoint Therapy Patent Publication

The European Patent Office published patent application EP3589653A1 titled 'Immune Checkpoint Therapy' filed by Ralf Kleef. The application covers therapeutic compositions classified under IPC C07K 16/28 (antibodies) and is designated for protection in all 35 EPC contracting states including EU member states. This A1 publication initiates the 18-month opposition window for third-party challenges.

Bispecific IgG Antibodies as T Cell Engagers for Cancer Treatment

The European Patent Office published patent application EP3470431A1 for Merus B.V., covering bispecific IgG antibodies engineered as T cell engagers for cancer treatment. The patent, filed by inventors Bakker, Van Loo, and Logtenberg, is classified under C07K 16/28 and designates 19 European states including major markets such as DE, FR, GB, IT, and NL.

Identification and Monitoring of Immunoglobulin J Chains

The European Patent Office published patent application EP3681907A1 for Mayo Foundation for Medical Education and Research, covering methods for identifying and monitoring Immunoglobulin J Chains. The application (Kind A1) was published March 25, 2026, with inventors David L. Murray and David R. Barnidge, designating 40 European contracting and validating states.

Seattle Project Corp antigen proteins targeting multiple targets, 25th Mar

Seattle Project Corp antigen proteins targeting multiple targets, 25th Mar

True EV Distribution v Xiaopeng Motors - Interlocutory Injunction Refused

Federal Court of Australia refused True EV Distribution's application for an interlocutory injunction against Shenzhen Xiaopeng Motors and related entities. The applicants sought to restrain Xiaopeng from appointing alternative distributors or distributing vehicles in Australia outside their existing agreement dated May 2024. The Court dismissed the application and ordered the applicants to pay the respondents' costs. A final hearing is listed for 3 weeks commencing 6 October 2026.